backOIG Issues Report Finding that Medicare Advantage Insurers Received Billions for Diagnoses Reported Only on Health Risk Assessments
A recent OIG report found that diagnoses reported in 2022 Medicare Advantage (MA) encounter data based only on health risk assessments (HRA) and HRA-linked chart reviews resulted in CMS making additional risk-adjusted payments of about $7.5 billion in 2023 (the Report). Of that $7.5 billion, OIG estimates that $4.8 billion was driven by in-home HRAs and HRA-linked chart reviews. The Report continues OIG’s recent work on risk adjustment encounter data supporting payments to MA organizations, including past reports on estimates of apparently disproportionate MA payments resulting from the use of HRAs (particularly in-home HRAs) and chart reviews.
Background on MA Risk-Adjusted Payments
CMS pays private MA organizations to administer MA plans on a capitated (fixed) basis to pay for the expenses of caring for enrollees on a prospective basis. The payments are risk adjusted to pay MA organizations more for enrollees who are expected to have higher health costs, based on an enrollee’s demographics and diagnoses codes submitted by the MA organizations. As a result, inaccurate and/or inflated diagnoses can result in MA organizations receiving inflated MA payments.
Diagnoses supporting risk-adjusted payments are required to be documented in enrollees’ medical records. These medical records are generated from initial and annual HRAs. CMS encourages providers to use HRAs as a tool to collect information from enrollees about their health status, health risks, and daily activities so they can develop, reassess, and adjust plans of care as necessary. HRAs may occur at a facility during an annual visit to a provider, at a patient’s home, or via telehealth.
In-Home HRAs and HRA-Linked Chart Reviews Disproportionately Drove Risk-Adjusted Payments Arising Only from HRAs and HRA-Linked Chart Reviews
A prior OIG report in September 2020 raised questions as to whether MA organizations use HRAs or similar assessments to maximize risk-adjusted payments rather than improve patient care. For instance, OIG previously found that diagnoses reported only on HRAs generated $2.6 billion in risk adjusted payments based on the 2016 encounter data, and that $2.1 billion of those payments arose from in-home HRAs. In the prior report, OIG raised concerns that many of the in-home HRAs were conducted by third-party vendors that MA companies partnered with and that diagnoses from those HRAs may not be as accurate.
OIG’s Report found that diagnoses reported only on HRAs and HRA-linked chart reviews resulted in an estimated $7.5 billion in risk-adjusted payments for 2023. The fact that these diagnoses were not referenced in any other medical records raised questions for OIG of whether: (1) the diagnoses were inaccurate and thus the payment improper; or (2) the enrollees did not receive necessary medical care for the conditions documented only on the HRAs or HRA-linked chart reviews.
OIG’s Report identified several facts that raise questions as to whether the in-home HRAs resulting in billions in additional payments contain accurate diagnoses, including:
- In-home HRAs and the subset of chart reviews that relied upon in-home HRAs generated an estimated $4.2 billion of the $7.5 billion in risk-adjusted payments.
- On average, MA organizations generated $1,869 in estimated risk adjusted payments from an in-home HRA, or more than five times the $365 in estimated risk-adjusted payments arising from each facility HRA.
- In-home HRAs only accounted for thirteen percent of the HRA and HRA-linked chart review records in the 2022 MA encounter data.
- In-home HRAs disproportionately drove certain of the top thirteen health condition diagnoses that drove 75% of the estimated $7.5 billion in 2023 risk adjusted payments from HRAs and HRA-linked chart reviews.
- Twenty MA organizations covering half of the enrollees received a disproportionate 80% of the payments.
At the policy level, OIG made certain policy recommendations. CMS concurred in OIG’s recommendation that CMS determine whether certain diagnoses that drove payments from in-home RAs and HRA-linked chart reviews may be more susceptible to misuse. However, CMS did not concur in OIG’s recommendation that CMS impose additional restrictions on the use of diagnoses reported only on in-home HRAs or related chart reviews. CMS also did not concur with OIG’s recommendation that CMS conduct audits to validate diagnoses reported only on in-home HRAs and related chart reviews.
The Report highlights are available here, and the full Report is available here.
Reporter, Christopher C. Jew, Los Angeles, + 1 213 443 4336, cjew@kslaw.com.
Also in the News
Key Takeaways from King & Spalding Health Law & Policy Forum West
On September 30, 2024, King & Spalding held its Annual Health Law & Policy Forum West. The Forum featured industry go-to leaders as they focused on pressing issues including developments in complex and innovative healthcare transaction structures, implications of emerging digital health and AI developments, finding revenue through creative managed care strategies, effective responses to changing government enforcement priorities, employment law trends, and how the recent SCOTUS decision in Loper Bright will affect future legal challenges to government regulation. Key takeaways from the Forum are available here.